Solid Biosciences Inc
SLDB6.520USD
+0.290+4.65%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
507.80MValor de mercado
PerdaP/L TTM
Mais detalhes de Solid Biosciences Inc Empresa
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Informações de Solid Biosciences Inc
Código da empresaSLDB
Nome da EmpresaSolid Biosciences Inc
Data de listagemJan 26, 2018
CEOCumbo (Alexander)
Número de funcionários100
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 26
Endereço500 Rutherford Avenue
CidadeCHARLESTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02129
Telefone16173374680
Sitehttps://www.solidbio.com/
Código da empresaSLDB
Data de listagemJan 26, 2018
CEOCumbo (Alexander)
Executivos da empresa Solid Biosciences Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
219.15K
-129171.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
97.86K
-56665.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
77.59K
-41620.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
70.33K
-38883.00%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
60.21K
-37155.00%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+1860.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
219.15K
-129171.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
97.86K
-56665.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
77.59K
-41620.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
70.33K
-38883.00%
Detalhamento da receita
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: ter, 18 de nov
Atualizado em: ter, 18 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Outro
52.47%
Investidores
Investidores
Proporção
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Outro
52.47%
Tipos de investidores
Investidores
Proporção
Investment Advisor
38.87%
Hedge Fund
23.54%
Investment Advisor/Hedge Fund
18.48%
Private Equity
15.19%
Venture Capital
7.46%
Research Firm
2.38%
Individual Investor
1.13%
Bank and Trust
0.13%
Pension Fund
0.07%
Participação acionária institucional
Atualizado em: seg, 5 de jan
Atualizado em: seg, 5 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
257
82.72M
106.17%
-17.41M
2025Q3
245
82.26M
105.58%
-6.26M
2025Q2
237
81.08M
104.59%
+27.37M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Perceptive Advisors LLC
11.83M
15.19%
-73.11K
-0.61%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.15%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
7.42M
9.52%
--
--
Sep 30, 2025
RA Capital Management, LP
5.81M
7.46%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.06M
5.21%
-309.31K
-7.08%
Sep 30, 2025
Adage Capital Management, L.P.
4.00M
5.13%
-2.73M
-40.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.08M
3.96%
-281.70K
-8.37%
Sep 30, 2025
Vestal Point Capital, LP
2.98M
3.82%
+1.47M
+97.67%
Sep 30, 2025
Fidelity Management & Research Company LLC
2.91M
3.74%
-264.27K
-8.31%
Sep 30, 2025
Citadel Advisors LLC
2.59M
3.33%
+69.40K
+2.75%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
iShares Neuroscience and Healthcare ETF
0.52%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção0.52%
iShares Micro-Cap ETF
Proporção0.06%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
iShares Biotechnology ETF
Proporção0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.02%
Avantis US Small Cap Equity ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Data
Data ex-dividendo
Tipo
Proporção
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
